Voya Investment Management LLC Has $29.07 Million Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Voya Investment Management LLC cut its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 7.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,400,243 shares of the company's stock after selling 179,920 shares during the quarter. Voya Investment Management LLC owned 0.49% of Elanco Animal Health worth $29,067,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. lifted its position in shares of Elanco Animal Health by 2.1% in the 4th quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock worth $524,000 after buying an additional 900 shares during the last quarter. Arizona State Retirement System boosted its stake in Elanco Animal Health by 0.8% in the fourth quarter. Arizona State Retirement System now owns 143,462 shares of the company's stock valued at $1,737,000 after acquiring an additional 1,166 shares during the period. MTM Investment Management LLC raised its position in shares of Elanco Animal Health by 9.3% during the 4th quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock worth $172,000 after purchasing an additional 1,200 shares during the period. Freedom Investment Management Inc. lifted its holdings in shares of Elanco Animal Health by 9.1% in the 4th quarter. Freedom Investment Management Inc. now owns 20,746 shares of the company's stock worth $251,000 after purchasing an additional 1,725 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after purchasing an additional 1,894 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Analyst Ratings Changes

ELAN has been the topic of a number of recent research reports. Barclays cut their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Morgan Stanley decreased their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Stifel Nicolaus cut their price target on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Piper Sandler reduced their price objective on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Finally, UBS Group lowered their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $14.67.

Insider Buying and Selling

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was purchased at an average price of $10.20 per share, with a total value of $102,000.00. Following the purchase, the director now owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.89% of the company's stock.

Elanco Animal Health Price Performance

Shares of ELAN stock traded up $0.35 during mid-day trading on Friday, hitting $9.82. 1,568,114 shares of the stock traded hands, compared to its average volume of 4,932,513. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company's 50-day simple moving average is $9.90 and its 200-day simple moving average is $11.52. The firm has a market cap of $4.87 billion, a price-to-earnings ratio of 24.54, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the firm earned $0.08 earnings per share. Elanco Animal Health's revenue was down 1.4% on a year-over-year basis. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.